

*Applicant: Phillips et al.
Application Serial No. 09/735,363
Amendment and Response to Final Office Action
Page 2 of 7*

AMENDMENTS TO THE CLAIMS

This listing of the claims will replace all prior versions, and listings, of claims in the application:

1. (Previously Presented) A composition comprising a 3'-OH, 5'-OH synthetic phosphodiester nucleotide sequence, a chemotherapeutic agent, and a pharmaceutically acceptable carrier, wherein the synthetic phosphodiester nucleotide sequence is selected from the group consisting of SEQ ID NOs:8-10, 25, 26, 41-43, 45 and 46.

2-9. (Cancelled)

10. (Previously Presented) The composition of Claim 1, wherein the chemotherapeutic agent is an antimetabolite, an alkylating agent, or a hormone antagonist.

11-58. (Cancelled)

59. (Previously presented) The composition of Claim 1, wherein the synthetic phosphodiester nucleotide sequence is SEQ ID NO:8.

60. (Cancelled)

61. (Previously presented) The composition of Claim 1, wherein the synthetic phosphodiester nucleotide sequence is SEQ ID NO:10.

62. (Previously presented) The composition of Claim 1, wherein the synthetic phosphodiester nucleotide sequence is SEQ ID NO:25.

63-64. (Cancelled)

Applicant: Phillips et al.
Application Serial No. 09/735,363
Amendment and Response to Final Office Action
Page 3 of 7

65. (Previously presented) The composition of Claim 1, wherein the synthetic phosphodiester nucleotide sequence is SEQ ID NO:42.

66. (Previously presented) The composition of Claim 1, wherein the synthetic phosphodiester nucleotide sequence is SEQ ID NO:43.

67. (Previously presented) The composition of Claim 1, wherein the synthetic phosphodiester nucleotide sequence is SEQ ID NO:45.

68. (Cancelled)

69. (Previously Presented) A composition comprising a 3'-OH, 5'-OH synthetic phosphodiester nucleotide sequence, a chemotherapeutic agent, and a pharmaceutically acceptable carrier, wherein the synthetic phosphodiester nucleotide sequence is selected from the group consisting of SEQ ID NOs:8-10, 25, 26, 41-43, 45 and 46, and the chemotherapeutic agent is an antimetabolite, an alkylating agent, or a hormone antagonist.

70. (Previously Presented) The composition of Claim 69, wherein the synthetic phosphodiester nucleotide sequence is SEQ ID NO:8.

71. (Previously Presented) The composition of Claim 69, wherein the synthetic phosphodiester nucleotide sequence is SEQ ID NO:9

72. (Previously Presented) The composition of Claim 69, wherein the synthetic phosphodiester nucleotide sequence is SEQ ID NO:10.

73. (Previously Presented) The composition of Claim 69, wherein the synthetic phosphodiester nucleotide sequence is SEQ ID NO:25.

74. (Previously Presented) The composition of Claim 69, wherein the synthetic phosphodiester nucleotide sequence is SEQ ID NO:26.

*Applicant: Phillips et al.
Application Serial No. 09/735,363
Amendment and Response to Final Office Action
Page 4 of 7*

75. (Previously Presented) The composition of Claim 69, wherein the synthetic phosphodiester nucleotide sequence is SEQ ID NO:41.

76. (Previously Presented) The composition of Claim 69, wherein the synthetic phosphodiester nucleotide sequence is SEQ ID NO:42.

77. (Previously Presented) The composition of Claim 69, wherein the synthetic phosphodiester nucleotide sequence is SEQ ID NO:43.

78. (Previously Presented) The composition of Claim 69, wherein the synthetic phosphodiester nucleotide sequence is SEQ ID NO:45.

79. (Previously Presented) The composition of Claim 69, wherein the synthetic phosphodiester nucleotide sequence is SEQ ID NO:46.

80. (Previously Presented) The composition of Claim 1, wherein the synthetic phosphodiester nucleotide sequence is SEQ ID NO:9.

81. (Previously Presented) The composition of Claim 1, wherein the synthetic phosphodiester nucleotide sequence is SEQ ID NO:26.

82. (Previously Presented) The composition of Claim 1, wherein the synthetic phosphodiester nucleotide sequence is SEQ ID NO:41.

83. (Previously Presented) The composition of Claim 1, wherein the synthetic phosphodiester nucleotide sequence is SEQ ID NO:46.

84-119. (Cancelled).